ONESOURCE Onesource Specialty Pharma Q3 FY25 results (Oct–Dec 2024) and concall
OneSource Specialty Pharma delivered a strong inaugural quarter post-listing, characterized by significant margin expansion driven by its biologics and drug-device combination (DDC) business. Management is aggressively positioning the company as a leading specialty CDMO, particularly in the GLP-1 space, with massive capacity expansions planned over the next 3-4 years. The company is focused on deleveraging and optimizing its balance sheet following a complex restructuring process.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 |
|---|---|
| Revenue | 393 |
| EBITDA | 142 |
| Net profit | -69 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
